Teva changes leadership in Americas unit based in North Wales

Teva Pharmaceuticals Industries Ltd., said Monday newly installed chief executive officer Jeremy Levin is shaking up the leadership of the company's Americas unit, which is based in North Wales, Montgomery County.

Teva is the world leader in generic pharmaceutical sales, but that title is jeopardy as competitors fight for greater share of the expanding market for cheaper, copy-cat medicine.

The company said that Bill Marth, who had led the unit, will retire at the end of 2013. He is being replaced by Allan Oberman, whose title will be president and CEO of Teva Americas Generics.

One slight difference is that Marth had led all of Teva's efforts in the western hemisphere, with branded and generic drugs, but that chore became more complicated with the 2011 acquisition of Frazer-based Cephalon for $6.5 billion.

Oberman will report directly to Levin. Earlier this year, Levin promoted Oberman to the Americas unit after he had guided the Teva's unit for Eastern Europe, Middle East, Israel and Africa. Oberman will also be responsible for Teva’s Latin American businesses.

Teva also said Jill DeSimone was appointed to the newly created position of senior vice president and general manager of Teva Global Women’s Health.

“These changes are part of our ongoing process to build a premier leadership team and reshape Teva,” Levin said in a company statement. “Allan brings extensive experience in global generics to the company’s Americas teams. Jill brings a great track record and many years of experience in building franchises in specialty medicine. We look forward to her contributions in leading our women’s health business. These changes underlie our commitment to build, in a disciplined fashion, a world class business and provide much needed medicines to patients around the world."

Like Levin, DeSimone joins Teva after working for Bristol-Myers Squibb, most recently as senior vice president for U.S. commercialization.

The company said Marth will serve as a senior advisor to Dr. Levin until his retirement.

“We greatly appreciate the contributions that Bill has made to Teva over the years, most recently leading the Teva businesses in the Americas," Levin said in the statement. "During this time, the company experienced significant growth. We thank him for his tremendous service to the company and look forward to working with him over the next year in his new capacity as a core advisor.”